Recognising the constellation of facial/arm swelling, distended veins and dyspnoea in someone with (or at risk of) thoracic cancer is the whole game — SVCO is a clinical diagnosis that must trigger urgent action before imaging.

Severity grading is the pivot of the pathway: stridor or cerebral signs make SVCO a true airway/neurological emergency requiring blue-light transfer and immediate steroid, whereas a gradual onset with collateral formation can often be worked up (including tissue diagnosis) before definitive treatment. The rate of onset matters because slowly developing obstruction allows venous collaterals to decompress the system, while a rapid occlusion does not.

The cause dictates definitive treatment: a chemo-sensitive tumour (small-cell lung cancer, lymphoma, germ-cell) may respond rapidly to chemotherapy, a thrombotic SVCO around a line may need anticoagulation and line removal rather than a stent, and a benign cause changes the prognosis entirely — which is why a tissue diagnosis is sought wherever the airway allows.

Contrast CT defines whether the obstruction is extrinsic compression, intraluminal tumour or thrombus, which determines whether a stent, anticoagulation or systemic therapy is the answer. Securing a tissue diagnosis before treatment matters because steroids and radiotherapy can obscure lymphoma histology — so in the stable patient, biopsy first; in the crashing patient, treat first.

Steroids reduce peritumoural oedema and the head-up position lowers venous pressure, giving symptomatic relief while the definitive treatment (usually a stent) is arranged.

NG12 singles out SVCO and stridor for immediate referral precisely because the 2-week-wait route is too slow for an airway-threatening, raised-venous-pressure emergency. Routing through acute oncology gets the patient to contrast CT and an interventional radiologist for stenting fastest, while keeping the diagnostic and treatment steps in parallel.

A stent treats the obstruction itself and works within hours, which is why it is now preferred over waiting for radiotherapy or chemotherapy to shrink the tumour — but the underlying-cancer treatment still matters because a chemo-sensitive tumour may be controlled definitively, and a thrombotic cause is managed pharmacologically rather than mechanically.

SVCO usually signals advanced malignancy with a limited prognosis, so even as the obstruction is relieved, parallel attention to breathlessness, steroid side-effects and advance care planning is part of good management rather than an afterthought — the visible, distressing nature of the presentation also makes psychological support important.

Relief from a stent or shrinking tumour is not always durable — re-thrombosis and stent occlusion reproduce the emergency, so the patient and carers need a clear safety-net to return immediately if facial swelling or breathlessness recur. Ongoing high-dose steroid carries its own risks that require active monitoring.